|
Study group
|
Total
|
Mean age (SD)a
|
Males (%)
|
Montelukastb (%)
|
Total drugs in DDDs (SD)c
|
|---|
|
All subjects
|
203,473
|
75.2 (9.7)
|
89,755 (44.1)
|
23,636 (11.6)
|
5.1 (4.6)
|
|
Montelukast
|
23,636
|
73.1 (9.0)
|
8964 (37.9)
|
-
|
6.3 (4.3)
|
|
Dementia medicine
|
6453
|
83.6 (7.7)
|
2502 (38.8)
|
602 (9.3)
|
5.6 (3.2)
|
|
Nursing homed
|
5970
|
77.8 (10.4)
|
2463 (41.3)
|
507 (8.5)
|
4.2 (3.5)
|
|
Death
|
61,434
|
82.7 (9.5)
|
31,152 (50.7)
|
5514 (9.0)
|
7.1 (6.3)
|
|
Parkinson’s medicine
|
7140
|
76.1 (9.3)
|
2849 (39.9)
|
955 (13.4)
|
6.3 (3.9)
|
|
Diabetes medicine
|
23,747
|
74.8 (9.1)
|
11,920 (50.2)
|
2887 (12.2)
|
7.8 (4.3)
|
-
aAge in 2014
-
bAt least two prescriptions
-
cMean Defined Daily Doses (DDDs) prescribed of any drug
-
dIt was assumed that a majority of those who did not receive any prescription for more than a year were admitted to a nursing home. Living in a nursing home can be used as a proxy for cognitive decline in that some 80% of Norwegian nursing home residents have dementia [11]
